Adrian L. Harris
University of Oxford
1115 Papers
15.4K Citations
Adrian L. Harris is an academic researcher from University of Oxford. The author has contributed to research in topics: Angiogenesis & Breast cancer. The author has an hindex of 170, co-authored 1084 publications. Previous affiliations of Adrian L. Harris include Royal College of Surgeons of England & Lawrence Livermore National Laboratory.
Chat about Author
Papers
ADGRL4/ELTD1 Silencing in Endothelial Cells Induces ACLY and SLC25A1 and Alters the Cellular Metabolic Profile.
David M Favara,Christos E. Zois,Syed Haider,Syed Haider,Elisabete Pires,Helen Sheldon,James S. O. McCullagh,Alison H. Banham,Adrian L. Harris +8 more
TL;DR: It is shown that ADGRL4/ELTD1 impacts core components of endothelial metabolism and regulates genes involved in endothelial differentiation/homeostasis and Notch signalling.
18
Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells.
TL;DR: Dipyridamole could exacerbate the nucleotide pool imbalance caused by CB3717, thereby potentiating its toxicity, and inhibition of nucleoside efflux may be an important aspect of its potentiation.
18
The use of bio-metal concentrations correlated with clinical prognostic factors to assess human breast tissues
TL;DR: This study shows that increased relative expressions of Zn, Fe and Ca are all associated with ER positive breast cancers and also indicates that the imbalance in iron concentration (deficiency) should be viewed as an important risk factor that is associated with aggressive features of the cancer.
18
Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues.
Juan Carlos Martinez,Marcus M Müller,Helen Turley,Graham Steers,Ludovine Choteau,Ji-Liang Li,Richard C.A. Sainson,Adrian L. Harris,Francesco Pezzella,Kevin C. Gatter +9 more
TL;DR: In this paper, a monoclonal antibody was raised to the internal domain of Delta-like ligand 4 (DLL4) and compared with other antibodies against both the internal and external domains of DLL4.
Cytosine arabinoside deamination in human leukaemic myeloblasts and resistance to cytosine arabinoside therapy.
TL;DR: Cytosine arabinoside deamination is unlikely to be an important mechanism of resistance in myeloblasts in vivo, although it may produce apparent resistance in vitro.
18